Positive earnings beat and strengthened balance sheet reduce near-term dilution risk ahead of multiple clinical data readouts in H2 2026. Key catalysts: budoprutug ITP data (June 2026), pMN and SLE data (Q4 2026), and CLYM116 PK/PD data (mid-2026). Monitor for buy-side momentum on pipeline progress.
Price Chart
Executive Summary
Climb Bio reported Q1 2026 EPS of -$0.20, beating consensus of -$0.26 by 23%, and reduced net loss to $13.7M from $20.8M a year ago. The company also secured a $110M private placement in April, extending cash runway into 2028, and announced positive budoprutug SC formulation data and FDA Fast Track Designation for pMN.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.20 beat consensus -$0.26 by 23%
- Net loss improved to $13.7M from $20.8M YoY
- Cash, cash equivalents, and marketable securities $146.3M as of March 31, 2026
- Completed $110M private placement on April 29, 2026, extending cash runway into 2028
- Budoprutug SC formulation showed robust B-cell depletion similar to IV; multiple-dose autoimmune study planned
- FDA granted Fast Track Designation for budoprutug in primary membranous nephropathy (pMN)
- Initial data from ITP trial expected June 2026; pMN and SLE data expected Q4 2026
Financial Impact
EPS beat of $0.06 per share on consensus; $110M capital infusion strengthens balance sheet
Risk Factors
- Clinical trial failures or delays could wipe out gains
- High cash burn rate; further financing may be needed beyond 2028
- Competition from other CD19 and APRIL-targeting therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210295 |
| Document: clym-20260507.htm | 0001193125-26-210295 |
| Document: 0001193125-26-210295-index-headers.html | 0001193125-26-210295 |
| Document: 0001193125-26-210295-index.html | 0001193125-26-210295 |
| Document: 0001193125-26-210295.txt | 0001193125-26-210295 |
| 8-K Data (Synthetic) | 0001193125-26-210295 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $10.92 | awaiting T+1 | — | $9.08 (−16.85%) |
Oct 23, 2026 3d ago | 8-K | $10.47 | awaiting T+1 | — | $9.08 (−13.28%) |
Oct 23, 2026 3d ago | Press Release | $10.34 | awaiting T+1 | — | $9.08 (−12.19%) |
Sep 22, 2026 4w ago | Institutional Cluster | $14.21 $12.52 | ▼ −11.89% | ▼ −11.17% | $9.08 (−36.10%) |
Sep 3, 2026 7w ago | 8-K | $14.59 $15.52 | ▲ +6.37% | ▲ +6.76% | $9.08 (−37.77%) |
Aug 14, 2026 10w ago | 8-K | $16.33 $17.44 | ▲ +6.80% | ▲ +7.27% | $9.08 (−44.40%) |
Aug 6, 2026 11w ago | 8-K | $14.00 $14.00 | · 0.00% | ▼ −0.61% | $9.08 (−35.14%) |
Jun 30, 2026 16w ago | 144 | $13.29 $12.90 | ▼ −2.93% | ▼ −2.80% | $9.08 (−31.68%) |
Jun 12, 2026 19w ago | 8-K | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $9.08 (+20.97%) |
Jun 12, 2026 19w ago | 424B5 | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $9.08 (+20.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers